ArticleJournal of microbiology and biotechnology2026
Full-Length 16S rRNA Amplicon Sequencing for the Simple and Simultaneous Detection of Multiple Probiotic Species in Commercial Products.
Article in Journal of microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To ensure efficacy and trust, probiotic strains in commercial products should be accurately identified. However, studies have consistently reported discrepancies between labeling and actual microbial composition. Therefore, we developed a full-length 16S rRNA amplicon sequencing workflow for species-level identification of probiotics. To optimize this workflow, four mock communities were analyzed using multiple pipelines and parameters; the workflow accuracy was evaluated. Optimal performance was achieved using Q10 filtering, the Emu pipeline with its default database, and a 0.1% relative abundance threshold. Subsequently, the workflow was applied to eight probiotic products, approximately 50% of which revealed labeling discrepancies with some labeled strains undetected. Furthermore, these results were compared and confirmed using PCR analysis. Despite some discrepancies, both approaches demonstrated overall consistency. Overall, the optimized sequencing workflow facilitates comprehensive species-level identification of probiotics within a single assay, providing a novel approach for quality control and labeling verification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.